Japanese Journal of Clinical Oncology, Vol 29, Issue 12 623-629, Copyright © 1999 by Foundation for Promotion of Cancer Research
N Oyama, H Akino, Y Suzuki, H Kanamaru, N Sadato, Y Yonekura and K Okada
BACKGROUND: To evaluate the clinical usefulness of [18F]fluorodeoxyglucose
positron emission tomography (FDG-PET) compared with histopathological
grading, clinical stage and serum prostatic specific antigen (PSA) level in
the detection and characterization of prostate cancer. METHODS: Forty-four
patients with histologically proven prostate cancer and five control
subjects with benign prostatic hyperplasia (BPH) were prospectively
investigated with FDG-PET prior to treatment. RESULTS: By visual
inspection, FDG accumulation was positive in 28 patients with prostate
cancer (sensitivity 64%), whereas all were negative in the control group.
FDG-PET in three patients with lymph node metastases did not show any high
intrapelvic accumulations corresponding to metastatic sites. Among 12
patients with multiple bone metastases which were detected with 99m-HMDP
bone scintigraphy, nine (75%) showed moderate to high FDG accumulation at
the sites of bone metastases. Quantitatively, FDG accumulation in prostate
cancer was significantly higher than in BPH and there was a tendency for
FDG uptake of tumors to be higher with higher histological Gleason grades.
Furthermore, FDG uptake in tumors with lymph node and/or bone metastasis
was significantly higher than that of localized stages. However, the
correlation between PSA and FDG uptake in the prostate cancer was very weak
for clinical relevance. CONCLUSIONS: Although FDG-PET was not sensitive
enough to detect prostate cancer in clinical use, it is suggested that
glucose metabolism in prostate cancer tended to be higher in patients with
tumors of advanced stages.
ORIGINAL ARTICLE
The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer
Department of Urology, Fukui Medical University, Japan. urono@fmsrsa.fukui-med.ac.jp
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Yun, S.-H. Bang, J. W. Kim, J. Y. Park, K. S. Kim, and J. D. Lee The Importance of Acetyl Coenzyme A Synthetase for 11C-Acetate Uptake and Cell Survival in Hepatocellular Carcinoma J. Nucl. Med., August 1, 2009; 50(8): 1222 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. TILKI, M. SEITZ, B. B. SINGER, S. IRMAK, C. G. STIEF, O. REICH, and S. ERGUN Molecular Imaging of Tumor Blood Vessels in Prostate Cancer Anticancer Res, May 1, 2009; 29(5): 1823 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Vavere, S. J. Kridel, F. B. Wheeler, and J. S. Lewis 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer J. Nucl. Med., February 1, 2008; 49(2): 327 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Oka, R. Hattori, F. Kurosaki, M. Toyama, L. A. Williams, W. Yu, J. R. Votaw, Y. Yoshida, M. M. Goodman, and O. Ito A Preliminary Study of Anti-1-Amino-3-18F-Fluorocyclobutyl-1-Carboxylic Acid for the Detection of Prostate Cancer J. Nucl. Med., January 1, 2007; 48(1): 46 - 55. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Wachter, S. Tomek, A. Kurtaran, N. Wachter-Gerstner, B. Djavan, A. Becherer, M. Mitterhauser, G. Dobrozemsky, S. Li, R. Potter, et al. 11C-Acetate Positron Emission Tomography Imaging and Image Fusion With Computed Tomography and Magnetic Resonance Imaging in Patients With Recurrent Prostate Cancer J. Clin. Oncol., June 1, 2006; 24(16): 2513 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Oyama, D. E. Ponde, C. Dence, J. Kim, Y.-C. Tai, and M. J. Welch Monitoring of Therapy in Androgen-Dependent Prostate Tumor Model by Measuring Tumor Proliferation J. Nucl. Med., March 1, 2004; 45(3): 519 - 525. [Abstract] [Full Text]
|
|
|
|
|
|
N. Oyama, T. R. Miller, F. Dehdashti, B. A. Siegel, K. C. Fischer, J. M. Michalski, A. S. Kibel, G. L. Andriole, J. Picus, and M. J. Welch 11C-Acetate PET Imaging of Prostate Cancer: Detection of Recurrent Disease at PSA Relapse J. Nucl. Med., April 1, 2003; 44(4): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dimitrakopoulou-Strauss and L. G. Strauss PET Imaging of Prostate Cancer with 11C-Acetate J. Nucl. Med., April 1, 2003; 44(4): 556 - 558. [Full Text] [PDF]
|
|
|
|
|
|
N. Oyama, H. Akino, H. Kanamaru, Y. Suzuki, S. Muramoto, Y. Yonekura, N. Sadato, K. Yamamoto, and K. Okada 11C-Acetate PET Imaging of Prostate Cancer J. Nucl. Med., February 1, 2002; 43(2): 181 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|